Maccura Biotechnology Co Ltd
Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such a… Read more
Maccura Biotechnology Co Ltd (300463) - Total Assets
Latest total assets as of September 2025: CN¥7.99 Billion CNY
Based on the latest financial reports, Maccura Biotechnology Co Ltd (300463) holds total assets worth CN¥7.99 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Maccura Biotechnology Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Maccura Biotechnology Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Maccura Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Maccura Biotechnology Co Ltd's total assets of CN¥7.99 Billion consist of 45.6% current assets and 54.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.4% |
| Accounts Receivable | CN¥1.61 Billion | 20.2% |
| Inventory | CN¥901.58 Million | 11.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥491.64 Million | 6.2% |
| Goodwill | CN¥51.04 Million | 0.6% |
Asset Composition Trend (2011–2024)
This chart illustrates how Maccura Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Maccura Biotechnology Co Ltd's current assets represent 45.6% of total assets in 2024, a decrease from 71.0% in 2011.
- Cash Position: Cash and equivalents constituted 8.4% of total assets in 2024, down from 20.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 20.2% of total assets.
Maccura Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Maccura Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
Optipharm.CO.LTD
KQ:153710
|
Korea | ₩42.32 Billion |
|
Bionet
TWO:1784
|
Taiwan | NT$3.10 Billion |
Maccura Biotechnology Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Maccura Biotechnology Co Ltd generates 0.32x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Maccura Biotechnology Co Ltd generates $ 1.59 in net profit.
Maccura Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.48 | 3.15 | 2.24 |
| Quick Ratio | 2.53 | 2.34 | 1.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.43 Billion | CN¥ 2.66 Billion | CN¥ 2.23 Billion |
Maccura Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Maccura Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.09 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -1.8% |
| Total Assets | CN¥7.98 Billion |
| Market Capitalization | $580.99 Million USD |
Valuation Analysis
Below Book Valuation: The market values Maccura Biotechnology Co Ltd's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Maccura Biotechnology Co Ltd's assets decreased by 1.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Maccura Biotechnology Co Ltd (2011–2024)
The table below shows the annual total assets of Maccura Biotechnology Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.98 Billion | -1.76% |
| 2023-12-31 | CN¥8.12 Billion | -0.52% |
| 2022-12-31 | CN¥8.16 Billion | +24.29% |
| 2021-12-31 | CN¥6.57 Billion | +3.17% |
| 2020-12-31 | CN¥6.36 Billion | +15.79% |
| 2019-12-31 | CN¥5.50 Billion | +20.64% |
| 2018-12-31 | CN¥4.56 Billion | +27.16% |
| 2017-12-31 | CN¥3.58 Billion | +32.79% |
| 2016-12-31 | CN¥2.70 Billion | +13.75% |
| 2015-12-31 | CN¥2.37 Billion | +95.03% |
| 2014-12-31 | CN¥1.22 Billion | +45.32% |
| 2013-12-31 | CN¥837.02 Million | +32.96% |
| 2012-12-31 | CN¥629.52 Million | +24.62% |
| 2011-12-31 | CN¥505.16 Million | -- |